{"prompt": "['Shapiro AD. Long-lasting recombinant factor VIII proteins for hemophilia A. Hematol Am Soc', 'Hematol Educ Program 2013;2013:37-43.', 'Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of', 'hemophilia. Haemophilia 2013;19:e1-47.', 'Stasyshyn O, Antunes S, Mamonov V, et al. Prophylaxis with anti-inhibitor coagulant', 'complex improves health-related quality of life in haemophilia patients with inhibitors: results', 'from FEIBA NF Prophylaxis Study. Haemophilia 2014;20:644-50.', 'Thornburg CD. Prophylactic factor infusions for patients with hemophilia: challenges with', 'treatment adherence. J Coagul Disord 2010;2:1-6.', 'Tj\u00f8nnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during', 'surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience.', 'Haemophilia 2004;10 (suppl 2):41-5.', 'Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis', 'regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia', 'A management. J Thromb Haemost 2012;10:359-67.', 'Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab', 'concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler J', '2013;19:593-600.', 'Von Mackensen S, Bullinger M. Development and testing of an instrument to assess the', 'quality of life of children with haemophilia in europe (haemo-qol). Haemophilia 2004;10', '(suppl 1) :17-25.', 'Von Mackensen SV, Gringeri A. Quality of life in hemophilia. In: Preedy VR, Watson RR, editors.', 'Handbook of disease burdens and quality of life measures. New York: Springer, 2010:1895-920.', 'Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence.', 'Ther Adv Hematol 2013;4:59-72.', 'W\u00f3jcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII', 'inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J', 'Emerg Med 2009;2:217-25.', 'World Federation of Hemophilia. Annual Global Survey Data 2014. Available from:', '  http://www1.wfh.org/GlobalSurvey/Public_AGSIAGS_Patients_Severity_EN.aspx.', 'Last', 'accessed: 16 August 2016', 'Wyrwich KW, Krishnan S, Poon JL, et al. Interpreting important health-related quality of life', 'change using the Haem-A-QoL. Haemophilia 2015;21:578-84.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '157 / Protocol MO39129, Version 3']['Appendix 1', 'Schedule of Activities', 'Early', 'Safety', 'Follow-', 'Termination /', 'Screening', 'Treatment', 'Study', 'up', 'Visit', 'Completion', '[a]', 'Wk -4 to', '15 m', '21 m', 'Unscheduled', 'Visits', 'Wk 1', 'Wk 2', 'Wk 3', 'Wk 5', '3 m', '6 m', '9 m', '12 m', '18 m', 'Wk 0', '[b]', '[b]', 'visit', '2 years', 'Time Window, days', '+ 2', '+2', '+2', '+7', '+7', '+ 7', '+ 14', '+ 14', '+ 30', '+ 30', '+ 30', 'Informed consent [c]', 'X', 'Inclusion / exclusion', 'X', 'criteria', 'Medical history and', 'X', 'demographics [d]', 'Physical examination', 'X', 'x', 'X', 'x', '[e]', 'Vital signs', 'X', 'X', 'X', 'X', 'Concomitant', 'X', 'X', 'X', 'X', 'X', 'medications [g]', 'Hematology and', 'X', 'X', 'X', 'X', 'blood chemistry [h,r]', 'Pregnancy test [i,r]', 'X', 'X', 'X', 'HIV and hepatitis', 'X', 'serology [j]', 'Anti-FVIII antibodies', 'x', 'X', 'X', 'X', 'X', '[k,r]', 'Anti-emicizumab', 'X', 'X', 'X', 'X', 'antibodies [l,r]', 'Emicizumab - F. Hoffmann-La Roche Ltd', '158 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}